




## STATE MEDICAID P&T COMMITTEE MEETING

Thursday, April 17, 2014

7:00 a.m. to 8:30 a.m.

Cannon Health Building

Room 114



# MINUTES

### Committee Members Present:

Kort Delost, R.Ph.

Lisa Hunt, R.Ph.

Roger Martenau, M.D.

Jameson Rice, Pharm.D.

Elizabeth Young, Pharm.D.

Julia Ozbolt, M.D.

### Committee Members Excused:

Bernadette Kiraly, M.D.

Ellie Brownstein, M.D.

Beth Johnson, R.Ph

### Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, RPh

Robyn Seely, Pharm.D.

Richard Sorenson, RN

### University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

### Other Individuals Present:

Akshaya Patel, Mylan

Scott Larson, BMS

Clayne Garrett, BIPI

Brody McKelvey, Utah AG office

Damiean Frarite, Mylan

Charissa Anne, J&J

Meeting conducted by: Kort Delost

---

1. **Review and Approval of March Minutes:** Kort Delost stated that the minutes for March were not included. For this reason, those meeting minutes will be included in May meeting, along with April minutes
2. **Housekeeping:** Lisa Hunt reminded people in attendance today to sign in. She also said that Bernadette Kiraly has told her that she will not be a member of the P&T committee for the next year. Lisa said that nominations are being accepted for potential members of the committee.
3. **Drug Utilization Review (DUR) Board update:** Robyn Seely reported that the April DUR Board discussed Daliresp, and next month the DUR board will review Juxtapid and Kynamro.
4. **Open Public Meeting Training:** Brody McKelvey presented a review of the open meetings act training. He described the aspects of the open public meetings requirements

and the individual rules about how open meetings must be conducted, when a meeting can be closed, steps that must be taken to notify the public and guidelines for taking minutes or recordings of the meetings. He encouraged any questions to be asked, and his office wants to help committees comply with the regulation.

**5. Committee discussion**

- a. Tim Morley questioned what happens if equipment fails in during the audio recording of the meeting.
- b. Brody said that the rules require that reasonable attempts be made to comply with the law, so as long as that attempt is made; the committee will be complying with the rule.
- c. Lisa Hunt passed out some information on the Roberts Rules of Order and training materials for members of the P&T committee.
- d. She also asked that the members fill out the conflict of interest forms provided.
- e. Lisa Hunt asked the board to nominate a committee member to be the chairperson. Roger Martenau made a motion for Kort Delost to be the chair again. Jameson Rice seconds the motion. All in favor.

6. **Antiemetics (scopolamine):** Melissa Archer presented a review of the antiemetic agent, scopolamine. Last month, this agent was not voted on, as it was not listed on the agenda prior to the meeting.

**7. Committee discussion**

- a. Lisa Hunt reviewed why this agent was not included with the vote last meeting.
- b. Roger Martenau made a motion that scopolamine is equally safe and effective. Elizabeth Young seconds the motion. All in favor.

8. **Epinephrine pen formulations:** Melissa Archer presented a review of the epinephrine containing emergency products. Peer-reviewed research regarding the safety and efficacy of each agent, disease-state treatment guidelines and Utah Medicaid utilization data was presented.

9. **Public Comment:** Akshaya Patel, PharmD, (Mylan, Epipen), discussed studies related the Epipen and comparisons between products.

10. **Other State report:** Lisa Hunt provided information about other states PDL preferred or non-preferred status on this category of drugs. She also presented utilization data in the past for Utah Medicaid.

**11. Committee discussion**

- a. Kort Delost said that having training pens included help with educating patients at the pharmacy.
- b. Tim Morley asked the drug rep, Akshaya Patel the reasons why the times for treatment vary between the Epipen and competitors. Dr Patel said that it may be how the product is formulated or the needle construction may vary.

- c. Kort Delost said that it is wise for prescribers to tell patients to take an oral antihistamine after using the injection. This can prevent a recurring reaction from occurring.
- d. Dr Patel said that it is always important to keep several pens around as the allergic reaction can recur after the injection has worn off.
- e. Discussion about the PA requirements for the product. Non Traditional Medicaid requires a PA, and PCN does not cover injectable products.
- f. Beth Young asked if there was a comparative efficacy test done. Melissa Archer said that there has not been a study comparing them. Each study has shown that each individual product is safe and efficacious.
- g. Beth Young said that because there is no comparative study, the committee can't make a decision of one agent being superior to another.
- h. Julia Ozbolt made a motion saying that due to lack of studies comparing the different agents, the agents are safe and efficacious. Roger Martenau seconds the motion. All in favor.
- i. Kort Delost asks if there is any other motions about usage that should be made. No one has other information to discuss or motions to present.

## 12. Meeting Adjourned

- 13. Next meeting is scheduled for May 15, 2014. Antihistamine 1<sup>st</sup> and 2<sup>nd</sup> generation agents will be discussed.

---

Minutes prepared by Trevor Smith

Recording available upon request, send email to [medicaidpharmacy@utah.gov](mailto:medicaidpharmacy@utah.gov)